Role of TLR4 as a prognostic factor for survival in various cancers: a meta-analysis

Bo Hao _, Zhen Chen, Baochen Bi, Miaomei Yu, Shuang Yao, Yuehua Feng, Yang Yu, Lili Pan, Dongmei Di, Guanghua Luo and Xiaoying Zhang

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:13088-13099. https://doi.org/10.18632/oncotarget.24178

Metrics: PDF 1472 views  |   HTML 2589 views  |   ?  


Bo Hao1,*, Zhen Chen2,*, Baochen Bi1,*, Miaomei Yu3, Shuang Yao3, Yuehua Feng3, Yang Yu3, Lili Pan3, Dongmei Di1, Guanghua Luo3 and Xiaoying Zhang1

1Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China

2Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China

3Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China

*These authors contributed equally to this work

Correspondence to:

Dongmei Di, email: [email protected]

Guanghua Luo, email: [email protected]

Keywords: Toll like receptor 4; solid tumor; prognosis; meta-analysis

Received: August 15, 2017     Accepted: December 04, 2017     Published: January 12, 2018


Background: Accumulating evidence showed that high expression of toll like receptor 4 (TLR4) was significantly associated with the outcome of patients with solid cancers. However, other studies failed to draw a similar conclusion. Thus, a systematic meta-analysis was performed to assess the prognostic value of TLR4 in solid tumors.

Results: Data from 15 studies and 1294 patients were enrolled. Among the 15 studies, 14 studies demonstrated the association between overall survival(OS) and TLR4 expression, and 7 studies described the relationship between disease-free survival(DFS) and TLR4 expression. High expression of TLR4 was significantly associated with poor OS (pooled hazard ratio (HR) = 2.05; 95% confidence interval (CI) (1.49, 2,49), P < 0.001). The results of meta regression analysis indicated that the subgroups of ethnic (PD = 0.924), tumor type (PD = 0.669), HR obtained method (PD = 0.945), analysis type (PD = 0.898), and cut-off value(PD = 0.835) were not the resource of heterogeneity. Moreover, patients with elevated TLR4 had a significantly worse DFS (pooled HR = 1.79; 95% CI (1.11, 2.88), P < 0.05).

Materials and Methods: We searched PubMed, Embase and the Cochrane Library (last update by April 18, 2017) to identify literatures evaluating the value of TLR4 in cancer patients. Combined hazard ratios (HRs) for OS and DFS were assessed using fixed-effects models and random effects models respectively.

Conclusions: The meta-analysis suggests that elevated expression of TLR4 is associated with poor OS and shorter DFS of patients with solid tumors. The results indicate that TLR4, as a novel prognostic biomarker in solid tumors, could potentially help to improve treatment decision-making of solid tumors in clinical.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24178